💨 Abstract
The Indian Pharmaceutical Market (IPM) has returned to negative volume growth in Q3FY25 after two quarters of positive growth, as per a Goldman Sachs report. While volume growth is below historical levels, strong pricing growth and new product launches are driving market performance. Goldman Sachs predicts a stabilization of IPM volume growth at low single digits in the coming quarters, with pricing benefits moderating starting next year.
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
Lebanon's Nawaf Salam to be designated PM, angering Hezbollah
17-year-old abducted from outside Gurugram church
Oil prices climb 2% to 4-month high on expected hit to China and India's Russian supplies
Nvidia faces revenue threat from new U.S. AI chip export curbs, analysts say
J&K: Retired PWD engineer booked for amassing wealth beyond means
Texas sues Allstate over data collection from cellphones
Crypto firm Tether and its founders finalising move to El Salvador
Soccer-Leverkusen's Boniface could return to fitness next week, Alonso says
Punjab to Rajasthan: A look at how India celebrated Lohri this year
Van driver killed with blow to head by unknown men in Gurugram village
Powered by MessengerX.io